Compare Adobe Systems Inc (ADBE) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Crispr Therapeutics AG — how do they compare? Adobe Systems Inc trades at $260.86 (market cap $104.82B), while Crispr Therapeutics AG trades at $54.07 (market cap $5.23B). The key difference: Adobe Systems Inc is far larger — about 20× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| ADBE | CRSP | |
|---|---|---|
Market Cap | $104.82B | $5.23B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $76.78 |
52-Week Low | $193.41 | $44.34 |
Enterprise Value | $106.26B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum above key support at $270. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability with 89.4% gross margins. Recent earnings beats and accelerating revenue growth contrast with mixed sentiment amid AI competition concerns and CEO transition uncertainty.
ADBE presents a compelling value proposition trading below analyst consensus targets with strong cash flow generation, though faces headwinds from AI disruption fears and sector volatility. The stock's current valuation at 15.62 P/E offers potential upside if execution continues, but requires monitoring of competitive threats and leadership stability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
